Fred Hutch Cancer Center is at the forefront of research and developing new treatments for multiple myeloma. Our researchers pioneered blood and marrow transplant (BMT), which is one of the most significant advances in treating multiple myeloma, lymphoma and other blood cancers.
Fred Hutch researchers continue to study and improve BMT for multiple myeloma, too, making it safer and more effective. We also pioneered the mini-transplant, a gentler version of transplant that is appropriate for some patients and reduces radiation exposure.
Multiple Myeloma Clinical Trials
Fred Hutch typically has over 750 active cancer clinical trials enrolling participants.
Clinical trials may allow some patients access to a promising new treatment, and help physicians and researchers learn more about a disease.
Multiple Myeloma Research
Our multiple myeloma research begins in the laboratory, where we study the biology of myeloma cells and test and develop potential new drugs and immunotherapies. It also includes clinical research in which our scientists test new methods for treating and caring for myeloma patients. This work spans years and decades as we track survivors’ quality of life after treatment.
Our Multiple Myeloma Researchers and Faculty
Our interdisciplinary researchers and clinicians work together to prevent, diagnose and treat multiple myeloma as well as other cancers and diseases.
Fred Hutch scientists are world experts on the complications of blood and marrow transplants, including infections and graft-versus-host disease. They are learning how these complications occur and developing better methods to prevent and treat them.
